Journal article
The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition
MJ Wall, G Wigmore, J Lopatář, BG Frenguelli, N Dale
Neuropharmacology | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2008
Abstract
Understanding the mechanisms and properties of purinergic signalling would be greatly assisted by the discovery of subtype selective and potent inhibitors of the NTPDase enzymes, which metabolise nucleotides such as ATP and ADP in the extracellular space. Currently ARL 67156 is the best available NTPDase inhibitor, but its relatively poor efficacy means that negative results are difficult to interpret. POM-1 (sodium polyoxotungstate) is a novel NTPDase inhibitor, which has shown promising results with the inhibition of recombinant NTPDases 1, 2 and 3. We have tested the effectiveness and physiological effects of POM-1 with cerebellar and hippocampal slices. Using the malachite green phosphat..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
We would like to thank Professor Christa Willer for the POM-1 sample and for comments on early drafts of the manuscript. We are also grateful to Dr. Rob Eason and Stephanie zur Nedden for assistance with the HPLC experiments. Jan Lopatar is funded by Epilepsy Research UK.